Pain associated with oral squamous cell carcinoma (oral SCC) decreases quality of life and survival. The interaction between cancer and the peripheral nerves is known to initiate and amplify pain and contribute to carcinogenesis. Schwann cells envelop peripheral nerves and are activated in response to neuronal damage. The contributions of Schwann cells to oral SCC progression and pain are unknown.
Introduction
Oral squamous cell carcinoma (oral SCC) is painful and significantly impairs oral function and decreases quality of life in patients (Schmidt, 2014; Schmidt et al., 2010) . Cancer pain is driven by the interaction between the cancer and peripheral nerves. Cancer releases algogenic mediators that excite and sensitize primary afferent neurons (Schmidt, 2014; Schmidt et al., 2010; Viet and Schmidt, 2010) . Cancer invades and spreads along the nerve (i.e., neural invasion, NI), leading to nerve injury and neuropathic pain (Mantyh, 2014; Yeh et al., 2016) . Oral SCC pain could also be induced by pathological nerve sprouting into the tumor (Mantyh, 2014) . However, current studies on oral SCC-nerve interaction focus only on the interaction between cancer and primary afferent neurons; the role of Schwann cells is overlooked.
Schwann cells are the most prevalent cell type in peripheral nerves, comprising 90% of the endoneurial space (Campana, 2007) . Schwann cells are plastic; they become activated as evidenced by dedifferentiating, proliferating, and migrating in response to peripheral insults such as inflammation or nerve injury (Gosselin et al., 2010; Jessen et al., 2015; Scholz and Woolf, 2007; Ydens et al., 2013) . They provide neuronal guidance and promote axonal growth during nerve regeneration and repair (Bhatheja and Field, 2006; Clements et al., 2017; Jessen et al., 2015) . The process of nerve regernation in which Schwann cells play a critical role drives persistent neuropathic pain (Xie et al., 2017) . Schwann cells are activated under hypoxic conditions and in the presence of pancreatic, colon, gastric and adenoid cystic carcinoma cells (Deborde et al., 2016; Demir et al., 2014 Demir et al., , 2016 . Activated Schwann cells promote cancer growth, invasion, dispersion, and secrete neurotrophic factors, chemokines/ cytokines, proteases, and adhesion molecules (Bunimovich et al., 2017; Deborde et al., 2016; Deborde and Wong, 2017; Demir et al., 2014 Demir et al., , 2017 . Schwann cells recruit cancer cells to the nerve, and may promote neuronal sprouting into the cancer (Deborde et al., 2016; Deborde and Wong, 2017) . Some neurotrophic factors and pro-inflammatory cytokines released by activated Schwann cells could directly excite and sensitize primary afferent neurons (Gosselin et al., 2010; Ji et al., 2016; Scholz and Woolf, 2007) . These findings suggest that Schwann cells could be activated by oral SCC and contribute to cancer progression and pain.
We showed previously that the oral SCC microenvironment contains high levels of adenosine 5 0 -triphosphate (ATP) in preclinical cancer models and human oral cancers (Ye et al., 2014b) . ATP rapidly degrades to adenosine by two cell surface enzymes CD73 (NT5E) and CD39 (ENTPD1) (Di Virgilio and Adinolfi, 2017) .
Both CD73 and CD39 are upregulated in cancer, suggesting more rapid conversion of ATP to adenosine in the cancer microenvironment compared to normal conditions, resulting in adenosine accumulation (Di Virgilio and Adinolfi, 2017; Kazemi et al., 2017; Ohta, 2016) . Adenosine is a neurotransmitter that regulates glial development, differentiation and glia-neuron communication (Stevens et al., 2002) .
The adenosine receptor A2B (ADORA2B) is overexpressed in oral SCC cell lines and human cancer specimens, and its expression levels significantly correlate with oral SCC growth (Kasama et al., 2015; Yamano et al., 2008) . Adenosine is longthought to be an inhibitory neurotransmitter for nociceptive signaling (Sawynok, 2016) . However, recent studies show that sustained exposure to adenosine may underlie chronic pain by activating A2B receptors on circulating myeloid cells to release IL-6, which results in increased neuronal sensitivity and chronic pain (Hu et al., 2016) .
In the present study we hypothesize a reciprocal interaction between oral SCC and Schwann cells that promotes cancer progression and pain. We propose that oral SCC and Schwann cell interact with each other through adenosine signaling and that interaction can be modulated by the adenosine receptor A2B. We will examine whether IL-6 is a Schwann cell derived nociceptive mediator that can be modulated by the A2B receptor.
Materials and methods

Cell culture and chemicals
Human oral SCC (HSC-3), human dysplastic oral keratinocytes (DOK), and rat Schwann cells (RSC-96) were purchased from ATCC. Cell passages between 4 and 10 were used for all experiments. Cells were grown in Dulbecco's Modified Eagle's Medium (DMEM) with 4.5 g/L glucose, L-glutamine and sodium pyruvate (Gibco, Thermo Fisher Scientific), supplemented with 10% fetal bovine serum (FBS), 100 mg/mL streptomycin sulfate, and 100 U/mL penicillin G at 37 C in 5% CO 2 . A highly selective A2B antagonist PSB603 (>17000-fold selectivity over other adenosine receptors) was obtained from Tocris Bioscience. Adenosine and adenosine 5 0 -triphosphate (ATP) were purchased from Sigma-Aldrich.
Animals
Six to eight week-old female BALB/cJ mice (Jackson laboratories) were housed in a temperature-controlled, pathogen free room on a 12:12 light/dark cycle (6 AMe6 PM) with ad libitum access to food and water. (Scheff et al., 2017; Ye et al., 2011 Ye et al., , 2014a Ye et al., , 2014b Ye et al., , 2018 . HSC-3 cells were cultured until 90% confluence. Media were replaced with fresh serum free media 48 hours prior to collection of supernatant. Ca 2þ imaging was conducted on RSC-96 cells by applying DMEM for one minute, followed by HSC-3 cell supernatant for two minutes, and 100 mM of ATP (a positive control) for another 1 minute.
Cells were counted as HSC-3 supernatant responsive if the 340/380 ratio is ! 0.2 from baseline according to a published method (Ye et al., 2014b) .
Cell growth measurement with a real time cell analyzer (RTCA)
The real time growth kinetics of RSC-96 cells and HSC-3 cells were examined using the Real-Time Cell Analyzer (RTCA) (xCELLigence System, Roche Applied Science) according to published methods (Roshan Moniri et al., 2015) . After background recordings, 10k cells were added to each well of the plate. Cell growth was monitored for 18 hours to enter their logarithmic growth phase, before 100 mL control culture media, drug treatment, or cell inserts were added ( Fig. 2A) . For co-culture experiments ( Fig. 2A, Fig. 3A ), either HSC-3 (10k or 20k) or RSC-96 (10k or 20k) cells were placed into cell inserts (3-mm pore size, xCELLigence Systems). Cell impedance was recorded for an additional 48e72 hours. Cell growth rate (slope, delta cell index/over delta time) was calculated based on the most linear portion of the cell growth curve before the plateau, using the RTCA Software Package 1.2. At least 5 wells were used for each treatment.
Cell proliferation assay
Cell growth was further confirmed with CellTiter 96Ò Aqueous One Solution Reagent (Promega) following the manufacturer's instructions. Either HSC-3 or RSC-96 cells were seeded at a density of 10k cells/well in 96-well plates. After 24 hours in culture, cell inserts for 96-well plates (3-mm pore size, xCELLigence Systems) or drugs were added into each well. Cells were incubated for another 48 hours until cell proliferation was measured at 490 nm optical density (OD) using a microplate reader (Promega). For co-culture experiments, the same density of and RSC-96 (10k) cells was used ( Fig. 2A, Fig. 3A ). Experiments were performed in triplicates and were repeated twice.
Migration and invasion assays
Cell migration assays were performed using 6-well culture plates and transwell Boyden chambers with an 8-mm pore size according to the manufacturer's instructions (Corning, Fig. 2D , Fig. 3D ). For the invasion assays we used 6-well culture plates and matrigel coated Boyden chambers with 8-mm pore size (BD Biosciences, 
ATP and adenosine quantification
To measure the ATP and the adenosine production in both HSC-3 and RSC-96 cells, HSC-3 and RSC-96 cells (100k each) were co-cultured in a 6-well plate with cell culture inserts. Inserts containing DMEM were used as controls. Triplicate wells were used for each treatment. Forty-eight hours following co-culture, when the cells were confluent, the inserts were removed. Either HSC-3 or RSC-96 cells in the culture plate were washed twice with PBS. Cells were collected in RIPA buffer (Thermo Fisher Scientific) with 10% protease inhibitor cocktail (Thermo Fisher Scientific). Cell lysates were centrifuged at 13,000g for 10 min at 4 C. ATP concentration in RSC-96 and HSC-3 cell lysates was determined using ENLITEN ATP assay kit (Promega). Luminescence intensity was determined using a luminometer (Promega). Adenosine concentration in RSC-96 and HSC-3 cell lysates was measured using a fluorometric adenosine assay kit (BioVision) following the manufacturer's instructions. The fluorescent intensity of adenosine was measured using a SpectraMax M5 plate reader (Molecular Devices). All samples were run in duplicate. 
Real-time PCR
Immunofluorescent staining
RSC-96 cells were grown overnight at 37 C on 12-mm glass cover slips coated with 100 mg/mL Poly-L-ornithine (Sigma-Aldrich) and 6 mg/mL of laminin 
Supernatant collection and pain behavior assessment
To determine whether Schwann cells co-cultured with cancer cells can directly trigger a nociceptive response, we injected supernatant from control (DMEM)
RSC-96 cells and RSC-96 cells co-cultured with HSC-3 cells into the mouse hind paw and measured paw withdrawal thresholds. RSC-96 cell supernatant was prepared using a non-contact co-culture approach. 100k RSC-96 cells were seeded onto a 6-well culture plate. Cell culture inserts containing DMEM alone (control), or 100k HSC-3 cells (treatment) were then placed on top of the RSC-96 culture.
To prevent the contamination of release products from HSC-3 cells, two days following co-culture, cell inserts containing either DMEM or HSC-3 were discarded and RSC-96 growth media was replaced by 1 mL serum-free DMEM. Control RSC- Drug treated plates received 3 mL PSB603 stock dissolved in DMSO into 3 mL of clear serum-free DMEM (1 mM final concentration). Cells were treated for 24 hours before the supernatant was collected and centrifuged briefly to remove cell debris. 50 mL of fresh prepared supernatant was injected to the midplantar region of the mouse right hind paw under anesthesia with isoflurane. 6 mice received vehicle supernatant from the co-culture of RSC-96 and HSC-3 cells, and another 6 mice received supernatant from A2B antagonist PSB603 treated co-culture.
For the paw withdrawal assay, mice were allowed to acclimate to the behavior room, the experimenter, and the measuring device for 2 weeks before a baseline paw withdrawal threshold was taken. Supernatant-injected mice were placed individually in a plastic cage with a wire mesh floor. One hour was allowed for recovery from anesthesia and acclimation before testing. The mid-plantar right hind paw was stimulated with a series of von Frey fibers with logarithmically incremental stiffness (TouchTestÒ, North Coast Medical Inc.) using the up-anddown methods (Chaplan et al., 1994) . The von Frey fibers were held perpendicular to the testing surface with sufficient force to cause buckling. A positive response was considered if the paw was sharply withdrawn and if there was an immediate flinching upon removal of fiber. The fibers were presented at least 5 seconds apart to allow resolution of previous stimuli. Paw withdrawal thresholds were taken at every hour for three hours after injection. Three to six repetitive trials were averaged as the threshold for each mouse at different time points. Animals were randomly assigned into groups. The number of animals per group was determined based on our previous publications on behavioral measurement following HSC-3 supernatant injection (Lam and Schmidt, 2010; Ye et al., 2014b Ye et al., , 2018 . The experimenter who performed the behavior testing was blinded to treatment groups. behavioral responses to mechanical stimuli over time among groups were tested using two-way repeated ANOVA, followed by Sidak's post hoc test. The significance levels were set at P < 0.05, P < 0.01, or P < 0.001. Results were presented as mean AE standard error of the mean (SEM).
Statistical analysis
Results
Oral SCC cells induce hypertrophy and Ca 2D accumulation in Schwann cells
RSC-96 cells co-cultured with HSC-3 cells exhibited increased cytoplasmic area compared to control RSC-96 cells (P < 0.001, HSC-3 vs. DMEM, Fig. 1BeC sharp Ca 2þ increase in these cells (Fig. 1E) . 
Adenosine and the A2B receptor mediate Schwann cell proliferation and migration
To determine whether the observed changes in proliferation and migration of RSC-96 cells following co-culture with HSC-3 cells were mediated by adenosine and the A2B receptor, we first determined that the adenosine receptor A2B was expressed by RSC-96 cells although receptor expression levels were not altered by co-culture (Fig. 5AeD) . Addition of 1 mM adenosine in DMEM increased RSC-96 cell proliferation and migration compared to the DMEM control (P < 0.001 and P ¼ 0.02, respectively, Fig. 6AeB ) and the increase was inhibited in a dose dependent manner by addition of the A2B antagonist PSB603 (Fig. 6AeB) . Similarly, increased proliferation and migration of RSC-96 cells was observed when the cells were cocultured with HSC-3 cells, and the increase was reversed by addition of the A2B antagonist PSB603 into the HSC-3 culture (Fig. 6CeD) . 
Adenosine and the A2B receptor mediate oral SCC cell proliferation and migration
Addition of 1 mM of adenosine in DMEM increased HSC-3 cell growth rate (P < 0.001, Fig. 7A ) and migration (P < 0.001, Fig. 7B ) compared to the DMEM control, and the increased proliferation and migration induced by adenosine were inhibited by the A2B antagonist PSB603 in a dose dependent manner (Fig. 7AeB) . In the co-culture model, RSC-96 induced increased proliferation (P < 0.001) of HSC-3 cells; adding the A2B antagonist PSB603 into the HSC-3 culture significantly reduced HSC-3 cell growth (P < 0.001, Fig. 7C ). Adding the A2B antagonist PSB603 into the co-culture significantly reduced HSC-3 cell migration towards RSC-96 in a concentration dependent manner (P < 0.001, 1 mM PSB603þRSC-96 vs. RSC-96, P ¼ 0.04, 1 mM PSB603þRSC-96 vs. 100 nM PSB603þRSC-96, P ¼ 0.08, 100 nM PSB603þRSC-96 vs. RSC-96 Fig. 7D ).
Schwann cells and the A2B receptor modulate oral SCCinduced nociception
We previously showed that HSC-3 supernatant induced mechanical hypersensitivity when injected into mice (Scheff et al., 2017; Ye et al., 2014b) . To determine whether Schwann cells contribute to cancer pain, RSC-96 cells were co-cultured with HSC-3 cells for two days to induce Schwann cell activation. The cell culture inserts containing HSC-3 cells were discarded, fresh media was added, and the RSC-96 cells were cultured alone for two days before the supernatant was collected. Control RSC-96 cells were cultured in the same condition with inserts filled with DMEM in the absence of HSC-3 cells. Supernatant from control RSC-96 cells alone decreased mechanical thresholds from baseline in mice (P < 0.001) and the decrease was augmented with supernatant from RSC-96 cells co-cultured with HSC-3 cells at two hours following injection (P ¼ 0.03, Fig. 8A) . No difference was detected between the two groups three hours following injection (P ¼ 0.06). To examine whether HSC-3 and RSC-96 cell interaction induces nociceptive behavior in mice, and whether the A2B receptor antagonist can inhibit the resulted nociceptive behaviors, we injected supernatant from the HSC-3 and RSC-96 mixed co-culture with and without PSB603 treatment. The supernatant from the co-culture mix induced a decrease in mechanical thresholds from pre-injection baseline, lasted for at least three hours (P < 0.001, Fig. 8B ). Supernatant from the PSB603-treated co-culture significantly increased mechanical thresholds in mice compared to the control supernatant (Fig. 8B ).
Since the A2B receptor has been shown to modulate the expression of IL-6 (Merighi et al., 2017) , a nociceptive mediator, we investigated the effect of HSC-3 cells and the A2B antagonist on IL-6 mRNA and protein expression in RSC-96 cells. In noncontact co-culture with HSC-3 cells, IL-6 mRNA expression increased in RSC-96 cells compared to the DMEM control (P < 0.001, Fig. 8C ), and this increase was inhibited by addition of PSB603 to the cell co-culture media (P ¼ 0.002, Fig. 8C ). Expression of IL-6 protein in RSC-96 cells was also increased following co-culture with HSC-3 cells in inserts compared to the DMEM control (P < 0.001, Fig. 8DeE ), and this increase was inhibited by PSB603 treatment in the cell co-culture media (P ¼ 0.009, Fig. 8DeE ). 
Discussion
Here we investigated a bidirectional interaction between Schwann cells and oral SCC. Our study demonstrates that oral SCC activates Schwann cells. Oral SCCinduced activation of Schwann cells is characterized by cell body enlargement, increased migration and proliferation; these features are similar to the Schwann cell response to nerve injury (Scholz and Woolf, 2007) . We also show that Schwann cells facilitate oral SCC proliferation, migration, and invasion in vitro. Using a supernatant paw injection model, we demonstrate that oral SCC activated Schwann cells could induce nociceptive behaviors in mice.
Emerging evidence suggests a cancer-promoting role of Schwann cells. Consistent with our own findings, increased cancer migration and invasion induced by Schwann cells has been reported in pancreatic, prostate, and colon cancer studies (Deborde et al., 2016; Deborde and Wong, 2017; Sroka et al., 2016) . Schwann cells induce cancer spread and protrusion formation (Deborde et al., 2016) , and epithelialmesenchymal transition (EMT) (Fujii-Nishimura et al., 2018; Shan et al., 2016) .
Furthermore, Schwann cells contribute to increased nerve innervation (i.e., hyperinnervation) commonly seen in cancer (Deborde and Wong, 2017) because of their known function in inducing nerve branching, arborization, and outgrowth (Armati and Mathey, 2013; Jessen et al., 2008; Kidd et al., 2013) . Schwann cells are not only present within the axon, but are also present around neurites or nerve terminals (Kidd et al., 2013) , where they can make direct contact with cancer cells and help recruit cancer cells to the nerve (Deborde and Wong, 2017) . Removal of Schwann cells following chemical or surgical ablations of nerves might explain decreased tumor growth and progression in animal models of prostate, gastric, and pancreatic cancers (Magnon et al., 2013; Saloman et al., 2016; Zhao et al., 2014) . Additionally, Schwann cells might contribute to cancer progression by initiating the process of neural invasion (Azam and Pecot, 2016) . Schwann cells migrate towards pancreatic cancer cells before cancer migrate towards Schwann cells; and the presence of Schwann cells in pancreatic precancer sites is associated with increased frequency of neural invasion in malignant pancreatic cancers (Demir et al., 2014) .
Our data suggest that the Schwann cell-oral SCC interaction is mediated by adenosine and its receptor A2B. Growing evidence indicates that adenosine and receptor A2B potentially play a pathophysiological role in human cancer and might serve as novel therapy for cancer (Kazemi et al., 2017) . Receptor A2B in the tumor, fibroblasts, endothelial and immune cells increase cancer progression through immunosuppressive activity, tumor angiogenesis, proliferation, and metastasis (Kasama et al., 2015; Kazemi et al., 2017; Kumar, 2013; Ohta, 2016) . Our findings affirm that A2B activation favors cancer progression. We did not observe an upregulation of A2B receptors on Schwann cells co-cultured with oral SCC, suggesting that activation of A2B receptors alone is sufficient to mediate cell proliferation and migration. Activated A2B receptors have the ability to couple to either a G q protein or a G s subtype of Ga proteins to mediate different cellular functions (FernandezGallardo et al., 2016; Schulte and Fredholm, 2003) . A2B receptor activation has been shown to increase both mRNA and protein levels of IL-6, PLC, PKC-ε, PKC-d and p38 signaling, while inhibition of A2B receptor activation pharmacologically by the antagonist PSB603 was associated with a reduction in p38 phosphorylation and IL-6 secretion in microglial cells (Merighi et al., 2017) . Future studies are needed to pinpoint the downstream signaling pathway upon A2B activation in Schwann cells in the presence of oral SCC.
Our data show that Schwann cells co-cultured with oral SCC induce increased mechanical hypersensitivity in mice and IL-6 is one of the possible nociceptive mediators released by oral SCC activated Schwann cells. Schwann cells co-cultured with oral SCC released more IL-6 compared to control Schwann cells; the A2B receptor antagonist reduced IL-6 release from Schwann cells co-cultured with oral SCC. In parallel, the A2B receptor antagonist inhibited the nociceptive behavior induced by Schwann cells co-cultured with oral SCC. Adenosine can be either pronociceptive or analgesic depending on the type of receptor and cells it acts upon and the duration of its action (Hu et al., 2016; Sawynok, 2016) . Adenosine is known to trigger IL-6 release in many cell types and the A2B receptor modulates IL-6 production (Merighi et al., 2017; Wei et al., 2013) . Our findings are further supported by a recent study showing mice lacking an enzyme that breaks down adenosine had increased chronic pain (Hu et al., 2016) . Accumulated adenosine activates A2B receptors in myeloid cells and leads to an increase in circulating IL-6 and soluble IL-6 receptor, which causes STAT3 phosphorylation and TRPV1 expression in primary afferent neurons (Hu et al., 2016) . In pancreatic cancer, however, Schwann cell activation and increased IL-6 are negatively correlated with cancer pain (Demir et al., 2016 (Demir et al., , 2017 . The authors found greater abundance of Schwann cells in premalignant pancreatic intraepithelial neoplasia (not painful) compared to the painful pancreatic adenomas (Demir et al., 2014 (Demir et al., , 2016 . The authors suggest that pancreatic precancer is not painful due to IL-6 produced by activated Schwann cells, which blocks glial activation in the central nervous system (Demir et al., 2016) . However, the authors also report increased secretion of other known nociceptive mediators such as TNF-a, CCL2, IL-8 by activated Schwann cells (Demir et al., 2016) . IL-6 activates glial cells and causes nociceptive behaviors in many animal models (Dubovy et al., 2010; Ellis and Bennett, 2013; Hu et al., 2016; Moini-Zanjani et al., 2016; Scholz and Woolf, 2007; Serizawa et al., 2018; Ye et al., 2011; Zhang and An, 2007) . Similar to pancreatic precancer, patients with oral dysplasia usually do not report pain, while pain is a prominent feature accompanying oral SCC, especially oral SCC with NI Yeh et al., 2016) . Our data show that Schwann cells are activated more when exposed to oral SCC cells compared to oral precancer cells. While additional studies are needed to confirm the role of Schwann cell derived IL-6 in oral SCC induced pain, activated Schwann cells could release other nociceptive mediators such as NGF and TNF-a -two commonly reported Schwann cell mediators (Ji et al., 2016; Scholz and Woolf, 2007) . In addition, Schwann cells may indirectly induce increased cancer pain through promoting cancer growth and migration, which could lead to accumulation of cancer-derived pain mediators (Scheff et al., 2017; Schmidt et al., 2007 Schmidt et al., , 2010 Ye et al., 2011) proximal to the nerve terminals and axons.
Conclusions
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